Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Renal Cell 145Kidney Neoplasms 42Neoplasms 39Neoplasm Metastasis 35Breast Neoplasms 33Gastrointestinal Stromal Tumors 31Carcinoma, Non-Small-Cell Lung 22Prostatic Neoplasms 16Urinary Bladder Neoplasms 13Colorectal Neoplasms 12Brain Neoplasms 12Pancreatic Neoplasms 11Glioblastoma 11Carcinoma, Hepatocellular 11Melanoma 10Lung Neoplasms 10Carcinoma 10Stomach Neoplasms 8Neuroendocrine Tumors 8Thyroid Neoplasms 7Sarcoma 7Ovarian Neoplasms 7Multiple Myeloma 7Liver Neoplasms 7Adenoma, Islet Cell 7Small Cell Lung Carcinoma 6Leukemia, Myeloid, Acute 6Glioma 6Esophageal Neoplasms 6Clear-cell metastatic renal cell carcinoma 6

Interventions

Sunitinib 1Robotic Surgical Procedures 1Laparoscopy 1Everolimus 1Conversion to Open Surgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neuroendocrine Tumors × Sunitinib × Clear all
NCT02282059 2024-06-20

The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors

Pfizer

Completed
100 enrolled 13 charts
EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡